MetaCurUm Biotech

Executive Summary

MetaCurUm Biotech is a Swedish preclinical-stage biotechnology company founded in 2018 as a spin-off from Umeå University. The company is developing a novel monoclonal antibody that targets an oncogenic TGFβ signaling pathway to prevent cancer metastasis. Its lead program focuses on metastatic castration-resistant prostate cancer (mCRPC), an aggressive form of prostate cancer with limited treatment options. MetaCurUm is also developing companion biomarkers to enable patient selection and treatment monitoring, aiming to personalize therapy. The company is privately held, with no disclosed funding to date, and operates in the competitive antibody and biologics space. Given its early stage, MetaCurUm faces significant clinical and regulatory risks, but its innovative approach to targeting TGFβ—a key driver of metastasis—addresses a critical unmet need in oncology. The company's success will depend on advancing its lead candidate through preclinical validation, securing financing, and initiating clinical trials.

Upcoming Catalysts (preview)

• Q4 2026IND-Enabling Studies Initiation40% success
• Q2 2027Series A Funding Round30% success
• Q1 2028First-in-Human Trial Application20% success